Tumor-Derived Semaphorin 4A Improves PD-1–Blocking Antibody Efficacy by Enhancing CD8+ T Cell Cytotoxicity and Proliferation

Researchers demonstrated that histologically Sema4A-positive non–small cell lung cancer (NSCLC) responded significantly better to anti–programmed cell death 1 (PD-1) antibody than Sema4A-negative NSCLC.
[Science Advances]
Full Article

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News